IMNN

NASDAQ 已收盘

Imunon

0.54 USD
▼-0.03-5.22%
盘后 0.54 +1.70%
2026-11-20
市值
$3.47M
市盈率
—
EPS
-3.16
股息率
—
52 周区间
0.50 – 4.35
成交量
49.70K
Beta
2.08
目标价
15.20
52W 低 0.5052W 高 4.35
价格走势

公司简介

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develo...